{"id":33910,"date":"2020-09-10T15:42:14","date_gmt":"2020-09-10T13:42:14","guid":{"rendered":"https:\/\/wordpress-783423-2671269.cloudwaysapps.com\/?p=33910"},"modified":"2025-01-29T14:09:12","modified_gmt":"2025-01-29T13:09:12","slug":"dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2","status":"publish","type":"post","link":"https:\/\/www.cometis.de\/en\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\/","title":{"rendered":"<span id=\"2020\" class=\"Postdate\">10 September 2020<\/span> | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE"},"content":{"rendered":"<style>\n.zur\u00fcckbutton:before {<br \/>    display: inline-block;<br \/>    font-family: \"ETmodules\";<br \/>    content: \"4a\";<br \/>    color: #00225f;<br \/>    margin-right: 7px;<br \/>}<br \/>.zur\u00fcckbutton:hover:before {<br \/>    display: inline-block;<br \/>    font-family: \"ETmodules\";<br \/>    content: \"4a\";<br \/>    color: #d85710;<br \/>    margin-right: 7px;<br \/>}<br \/><\/style>\n<h1 style=\"text-align: justify;\">Ad hoc news<\/h1>\n<p><a class=\"zur\u00fcckbutton\" href=\"https:\/\/cometis.de\/en\/publication-archive-dermapharm\">to the archive<\/a><\/p>\n<h1><strong><em>Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE<\/em><\/strong><\/h1>\n<p>Gr\u00fcnwald, September 10, 2020 \u2013 Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) and BioNTech SE, Mainz, Germany, have agreed that their production subsidiaries will cooperate on producing a COVID-19 vaccine. The production capacities at Dermapharm will be available to the cooperation partners BioNTech SE and Pfizer Inc. already when production of the vaccine begins.<\/p>\n<p><strong>Contacts<\/strong><br \/>\nInvestor Relations &amp;<br \/>\nCorporate Communications<br \/>\nBritta Hamberger<br \/>\nPhone: +49 (0)89 \u2013 64186-233<br \/>\nFax: +49 (0)89 \u2013 64186-165<br \/>\nE-mail: <a href=\"mailto:ir@dermapharm.com\">ir@dermapharm.com<\/a><\/p>\n<p><strong>cometis AG <\/strong><br \/>\nClaudius Krause<br \/>\nPhone: +49 (0)611 \u2013 205855-28<br \/>\nFax: +49 (0)611 \u2013 205855-66<br \/>\nE-mail: <a href=\"mailto:ir@dermapharm.com\">ir@dermapharm.com <\/a><\/p>\n<div class=\"leseprobe-archiv\"><a title=\"Beitrag als PDF\" href=\"https:\/\/cometis.de\/wp-content\/uploads\/2020\/09\/EN_20200910_Ad-hoc_Biontech-FINAL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Read as PDF<\/a><\/div>\n<style> .leseprobe-archiv {color: #00225f !important; border-color: #00225f; position: relative; padding: 0.3em 1em; border: 1px solid; -webkit-border-radius: 3px; -moz-border-radius: 3px; border-radius: 3px; -webkit-transition: all 0.2s; -moz-transition: all 0.2s; transition: all 0.2s; padding:10px; width: 19%; text-align: center; margin-right: 10px; float:left;} .leseprobe-archiv:hover {background-color: #eee; border-color: #ffffff; cursor: pointer;}<\/style>\n","protected":false},"excerpt":{"rendered":"<p>Ad hoc news to the archive Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE Gr\u00fcnwald, September 10, 2020 \u2013 Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) and BioNTech SE, Mainz, Germany, have agreed that their production subsidiaries will cooperate on producing a COVID-19 vaccine. The production capacities at Dermapharm will be available [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":98872,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[221,90],"tags":[276],"class_list":["post-33910","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dermapharm-ad-hoc-news","category-news-en","tag-2020-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.2 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>10 September 2020 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE - cometis AG<\/title>\n<meta name=\"description\" content=\"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cometis.de\/en\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"10 September 2020 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE\" \/>\n<meta property=\"og:description\" content=\"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cometis.de\/en\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\/\" \/>\n<meta property=\"og:site_name\" content=\"cometis AG\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-10T13:42:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T13:09:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"171\" \/>\n\t<meta property=\"og:image:height\" content=\"31\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Assistenz cometis AG\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Assistenz cometis AG\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\\\/\"},\"author\":{\"name\":\"Assistenz cometis AG\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/person\\\/5359bae3178840cd846706150aa69cd1\"},\"headline\":\"10 September 2020 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE\",\"datePublished\":\"2020-09-10T13:42:14+00:00\",\"dateModified\":\"2025-01-29T13:09:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\\\/\"},\"wordCount\":117,\"publisher\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"keywords\":[\"2020\"],\"articleSection\":[\"Dermapharm Ad-Hoc News\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\\\/\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\\\/\",\"name\":\"10 September 2020 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE - cometis AG\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"datePublished\":\"2020-09-10T13:42:14+00:00\",\"dateModified\":\"2025-01-29T13:09:12+00:00\",\"description\":\"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cometis.de\\\/en\\\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"contentUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"width\":172,\"height\":172},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dermapharm Ad-Hoc News\",\"item\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/category\\\/dermapharm-ad-hoc-news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"10 September 2020 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/\",\"name\":\"cometis AG\",\"description\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#organization\",\"name\":\"cometis AG\",\"alternateName\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2024\\\/12-old\\\/Cometis-Mobile-Logo-1.png\",\"contentUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2024\\\/12-old\\\/Cometis-Mobile-Logo-1.png\",\"width\":171,\"height\":31,\"caption\":\"cometis AG\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/cometis-ag\\\/\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/cometisAG\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/person\\\/5359bae3178840cd846706150aa69cd1\",\"name\":\"Assistenz cometis AG\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g\",\"caption\":\"Assistenz cometis AG\"},\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/author\\\/assistenz-cometis-ag\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"10 September 2020 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE - cometis AG","description":"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cometis.de\/en\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\/","og_locale":"en_US","og_type":"article","og_title":"10 September 2020 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE","og_description":"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.","og_url":"https:\/\/www.cometis.de\/en\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\/","og_site_name":"cometis AG","article_published_time":"2020-09-10T13:42:14+00:00","article_modified_time":"2025-01-29T13:09:12+00:00","og_image":[{"width":171,"height":31,"url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","type":"image\/png"}],"author":"Assistenz cometis AG","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Assistenz cometis AG","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cometis.de\/en\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\/#article","isPartOf":{"@id":"https:\/\/www.cometis.de\/en\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\/"},"author":{"name":"Assistenz cometis AG","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/person\/5359bae3178840cd846706150aa69cd1"},"headline":"10 September 2020 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE","datePublished":"2020-09-10T13:42:14+00:00","dateModified":"2025-01-29T13:09:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cometis.de\/en\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\/"},"wordCount":117,"publisher":{"@id":"https:\/\/www.cometis.de\/en\/#organization"},"image":{"@id":"https:\/\/www.cometis.de\/en\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","keywords":["2020"],"articleSection":["Dermapharm Ad-Hoc News","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.cometis.de\/en\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\/","url":"https:\/\/www.cometis.de\/en\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\/","name":"10 September 2020 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE - cometis AG","isPartOf":{"@id":"https:\/\/www.cometis.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cometis.de\/en\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\/#primaryimage"},"image":{"@id":"https:\/\/www.cometis.de\/en\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","datePublished":"2020-09-10T13:42:14+00:00","dateModified":"2025-01-29T13:09:12+00:00","description":"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.","breadcrumb":{"@id":"https:\/\/www.cometis.de\/en\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cometis.de\/en\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cometis.de\/en\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\/#primaryimage","url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","contentUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","width":172,"height":172},{"@type":"BreadcrumbList","@id":"https:\/\/www.cometis.de\/en\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cometis.de\/en\/"},{"@type":"ListItem","position":2,"name":"Dermapharm Ad-Hoc News","item":"https:\/\/www.cometis.de\/en\/category\/dermapharm-ad-hoc-news\/"},{"@type":"ListItem","position":3,"name":"10 September 2020 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE"}]},{"@type":"WebSite","@id":"https:\/\/www.cometis.de\/en\/#website","url":"https:\/\/www.cometis.de\/en\/","name":"cometis AG","description":"Deutschlands f\u00fchrende Investor Relations Agentur","publisher":{"@id":"https:\/\/www.cometis.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cometis.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.cometis.de\/en\/#organization","name":"cometis AG","alternateName":"Deutschlands f\u00fchrende Investor Relations Agentur","url":"https:\/\/www.cometis.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","contentUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","width":171,"height":31,"caption":"cometis AG"},"image":{"@id":"https:\/\/www.cometis.de\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/cometis-ag\/","https:\/\/www.youtube.com\/user\/cometisAG"]},{"@type":"Person","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/person\/5359bae3178840cd846706150aa69cd1","name":"Assistenz cometis AG","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g","caption":"Assistenz cometis AG"},"url":"https:\/\/www.cometis.de\/en\/author\/assistenz-cometis-ag\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts\/33910","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/comments?post=33910"}],"version-history":[{"count":0,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts\/33910\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/media\/98872"}],"wp:attachment":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/media?parent=33910"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/categories?post=33910"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/tags?post=33910"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}